Healthcare provider profile · identity verified

Heidi Sharon Brookenthal, D.O.

Family Practice · CHICAGO, IL · NPI 1205911237

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	627	188
Amlodipine Besylate	Amlodipine Besylate	526	157
Hydrochlorothiazide	Hydrochlorothiazide	300	93
Lisinopril	Lisinopril	206	64
Metformin Hcl	Metformin Hcl	200	56
Albuterol Sulfate Hfa	Albuterol Sulfate	194	54
Simvastatin	Simvastatin	188	49
Gabapentin	Gabapentin	176	42
Losartan Potassium	Losartan Potassium	163	53
Metoprolol Succinate	Metoprolol Succinate	162	52
Levothyroxine Sodium	Levothyroxine Sodium	155	44
Omeprazole	Omeprazole	151	45
Fluticasone Propionate	Fluticasone Propionate	127	43
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	121	31
Furosemide	Furosemide	112	43
Potassium Chloride	Potassium Chloride	111	33
Ozempic	Semaglutide	101	24
Carvedilol	Carvedilol	95	28
Alendronate Sodium	Alendronate Sodium	91	27
Diclofenac Sodium	Diclofenac Sodium	80	26
Rosuvastatin Calcium	Rosuvastatin Calcium	79	24
Allopurinol	Allopurinol	78	23
Metoprolol Tartrate	Metoprolol Tartrate	74	22
Escitalopram Oxalate	Escitalopram Oxalate	72	19
Pantoprazole Sodium	Pantoprazole Sodium	69	21
Lovastatin	Lovastatin	67	21
Tramadol Hcl	Tramadol Hcl	66	15
Eliquis	Apixaban	65	16
Glipizide Er	Glipizide	65	17
Metformin Hcl Er	Metformin Hcl	64	23
Alprazolam	Alprazolam	63	14
Enalapril Maleate	Enalapril Maleate	60	18
Jardiance	Empagliflozin	60	18
Trazodone Hcl	Trazodone Hcl	60	14
Ibuprofen	Ibuprofen	59	20
Januvia	Sitagliptin Phosphate	55	12
Spironolactone	Spironolactone	54	16
Pravastatin Sodium	Pravastatin Sodium	53	15
Glipizide	Glipizide	51	15
Nifedipine Er	Nifedipine	51	13
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	49	15
Baclofen	Baclofen	49	14
Montelukast Sodium	Montelukast Sodium	48	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	12
Clonazepam	Clonazepam	44	suppressed
Chlorthalidone	Chlorthalidone	43	11
Sertraline Hcl	Sertraline Hcl	42	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	41	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	41	12
Valacyclovir	Valacyclovir Hcl	41	14
Warfarin Sodium	Warfarin Sodium	41	11
Atenolol	Atenolol	40	suppressed
Naproxen	Naproxen	38	15
Amitriptyline Hcl	Amitriptyline Hcl	36	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	11
Famotidine	Famotidine	33	11
Meloxicam	Meloxicam	33	suppressed
Breo Ellipta	Fluticasone/Vilanterol	32	suppressed
Bupropion Xl	Bupropion Hcl	32	suppressed
Symbicort	Budesonide/Formoterol Fumarate	32	suppressed
Azelastine Hcl	Azelastine Hcl	31	11
Ibu	Ibuprofen	30	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	30	suppressed
Mounjaro	Tirzepatide	29	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	29	suppressed
Benazepril Hcl	Benazepril Hcl	28	suppressed
Buspirone Hcl	Buspirone Hcl	28	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	suppressed
Trulicity	Dulaglutide	27	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	26	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Rybelsus	Semaglutide	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Hydrocortisone	Hydrocortisone	21	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Valsartan	Valsartan	19	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	18	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Prazosin Hcl	Prazosin Hcl	18	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Humalog Kwikpen U-100	Insulin Lispro	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	suppressed
Varenicline Tartrate	Varenicline Tartrate	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Lorazepam	Lorazepam	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	11
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Finasteride	Finasteride	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Fluconazole	Fluconazole	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Naloxone Hcl	Naloxone Hcl	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	12	suppressed
Azithromycin	Azithromycin	11	11
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error